What does the hiring of a well known trade dealmaker imply for the way forward for BioMarin Prescribed drugs? Can Eli Lilly’s blockbuster weight problems medication decrease the chance of diabetes? And can Recursion Pharma, the AI drug developer, reside as much as all of the hype?
We focus on all that and extra on this week’s episode of “The Readout LOUD.”
It’s a guest-free episode this week, giving Allison, Adam and Elaine ample time to talk concerning the administration shakeup at BioMarin, together with the announcement that James Sabry, the previous Roche dealmaker, was becoming a member of the corporate as its new chief enterprise officer. We are able to’t appear to go every week with out speaking about GLP-1 medicines, so in true type, Elaine walks us by new examine findings that confirmed Lilly’s Zepbound drastically lowered the chance of diabetes. We additionally focus on a separate examine that probably hyperlinks GLP-1 medicine to a better price of suicidal ideas.
Lastly, Adam and Elaine interrogate Allison about her deeply reported company profile of AI drug developer Recursion. Is all of the hype actual?
For extra on Lilly’s Zepbound diabetes examine, go right here. For a writeup of the suicide ideation examine, look right here. And Allison’s sweeping profile of Recursion will be discovered right here.
Make certain to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
